A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study

被引:1
作者
Rios-Tamayo, Rafael [1 ]
Soler, Juan Alfons [2 ]
Garcia-Sanchez, Ricarda [3 ]
Persona, Ernesto Perez [4 ]
Arnao, Mario [5 ]
Garcia-Guinon, Antoni [6 ]
Domingo, Abel [7 ]
Gonzalez-Pardo, Miriam [8 ]
de la Rubia, Javier [9 ,10 ,11 ]
Mateos, Maria Victoria [12 ]
机构
[1] Hosp Univ Puerta Hierro Majadahonda, Dept Hematol, Madrid, Spain
[2] Hosp Univ Parc Tauli Sabadell, Dept Hematol, Catalonia, Spain
[3] Hosp Virgen Victoria, Dept Hematol, Malaga, Spain
[4] Hosp Univ Navarra, Dept Hematol, Pamplona, Spain
[5] Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain
[6] Hosp Arnau Vilanova, Dept Hematol, Lleida, Spain
[7] Hosp Gen Granollers, Dept Hematol, Barcelona, Spain
[8] Janssen Cilag Espana, Med Dept, Madrid, Spain
[9] Hosp Univ & Politecn La Fe, Valencia, Spain
[10] Univ Catolica San Vicente Martir, Hematol Dept, Valencia, Spain
[11] CIBERONC CB16 12 00284, Valencia, Spain
[12] Hosp Univ Salamanca, Ctr Invest Canc IBMCC USAL CSIC, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain
关键词
Relapsed-refractory multiple myeloma; real-world; monoclonal antibodies; daratumumab; standard of care; LENALIDOMIDE PLUS DEXAMETHASONE; DARATUMUMAB; BORTEZOMIB; SURVIVAL; CARFILZOMIB; THERAPY; SAFETY;
D O I
10.1080/16078454.2023.2178997
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe the incorporation of monoclonal antibodies (mAb) in real-world (RW) practice for the treatment of patients with relapsed refractory multiple myeloma (RRMM) in a setting with other treatment alternatives. Methods This was an observational, multicenter, ambispective study of RRMM treated with or without a mAb. Results A total of 171 patients were included. For the group treated without mAb, the median (95% CI) progression-free survival (PFS) to relapse was 22.4 (17.8-27.0) months; partial response or better (>= PR) and complete response or better (>= CR) was observed in 74.1% and 24.1% of patients, respectively; and median time to first response in first relapse was 2.0 months and in second relapse was 2.5 months. For the group of patients treated with mAb in first or second relapse, the median PFS was 20.9 (95% CI, could not be evaluated) months; the >= PR and >= CR rates were 76,2% and 28.6%, respectively; and the median time to first response in first relapse was 1.2 month and in second relapse was 1.0 months. The safety profiles for the combinations were consistent with those expected. Conclusions The incorporation of mAb in RW practice for the treatment of RRMM has shown good quality and speed of response with a similar safety profile shown in randomized clinical trials.
引用
收藏
页数:11
相关论文
共 55 条
  • [1] High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
    Adams, Homer C., III
    Stevenaert, Frederik
    Krejcik, Jakub
    Van der Borght, Koen
    Smets, Tina
    Bald, Jaime
    Abraham, Yann
    Ceulemans, Hugo
    Chiu, Christopher
    Vanhoof, Greet
    Usmani, Saad Z.
    Plesner, Torben
    Lonial, Sagar
    Nijhof, Inger
    Lokhorst, Henk M.
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    Sasser, Amy Kate
    Casneuf, Tineke
    [J]. CYTOMETRY PART A, 2019, 95A (03) : 279 - 289
  • [2] [Anonymous], RF228132
  • [3] Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience
    Antonioli, Elisabetta
    Staderini, Michela
    Pilerci, Sofia
    Perfetto, Federico
    Cappelli, Francesco
    Allinovi, Marco
    Nozzoli, Chiara
    Attucci, Irene
    Buzzichelli, Alessandra
    Messeri, Maria
    Bosi, Alberto
    [J]. LEUKEMIA & LYMPHOMA, 2020, 61 (13) : 3255 - 3258
  • [4] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Bahlis, Nizar J.
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Ukropec, Jon
    Qi, Ming
    San-Miguel, Jesus
    [J]. LEUKEMIA, 2020, 34 (07) : 1875 - 1884
  • [5] Cedena M., 2019, EMERGENCIAS, V104, P1
  • [6] Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study
    Chang-Chan, D-Y-L
    Rios-Tamayo, R.
    Barranco, M. Rodriguez
    Redondo-Sanchez, D.
    Gonzalez, Y.
    Marcos-Gragera, R.
    Sanchez, M. J.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (07) : 1429 - 1439
  • [7] CTEP, 2012, COMMON TERMINOLOGY C
  • [8] Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
    Cuesta-Mateos, Carlos
    Alcaraz-Serna, Ana
    Somovilla-Crespo, Beatriz
    Munoz-Calleja, Cecilia
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 8
  • [9] Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
    Davies, Faith
    Rifkin, Robert
    Costello, Caitlin
    Morgan, Gareth
    Usmani, Saad
    Abonour, Rafat
    Palumbo, Antonio
    Romanus, Dorothy
    Hajek, Roman
    Terpos, Evangelos
    Cherepanov, Dasha
    Stull, Dawn Marie
    Huang, Hui
    Leleu, Xavier
    Berdeja, Jesus
    Lee, Hans C.
    Weisel, Katja
    Thompson, Michael
    Boccadoro, Mario
    Zonder, Jeffrey
    Cook, Gordon
    Puig, Noemi
    Vela-Ojeda, Jorge
    Farrelly, Eileen
    Raju, Aditya
    Blazer, Marlo
    Chari, Ajai
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (09) : 2325 - 2337
  • [10] Real-World Outcomes for Standard-ofCare Treatments in Patients with Relapsed/Refractory Multiple Myeloma
    Delforge, Michael
    Vekemans, Marie-Christiane
    Anguille, Sebastien
    Depaus, Julien
    Meuleman, Nathalie
    Van de Velde, Ann
    Van de Broek, Isabelle
    Strens, Danielle
    Van Hoorenbeeck, Sandra
    Moorkens, Evelien J.
    Diels, Jorks
    Ghilotti, Francesca
    Dalhuisen, Sander
    Vandervennet, Sophie
    [J]. BLOOD, 2021, 138